KLK3 and neoplasm: The D’Amico Risk group Classification (1) classifies patients into low-, intermediate-, and high-risk groups based on pretreatment prostate-specific antigen (PSA) level, biopsy Gleason score (GS), and clinical tumor (T) stage, all variables that are readily available to the treating physician.